PMID- 35491164
OWN - NLM
STAT- MEDLINE
DCOM- 20220503
LR  - 20220503
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 45
IP  - 5
DP  - 2022
TI  - Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with 
      Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab.
PG  - 590-595
LID - 10.1248/bpb.b21-00939 [doi]
AB  - The gut microbiome influences tumor response to immune checkpoint inhibitors 
      (ICIs). The proton pump inhibitors (PPI) significantly impair diversity of the 
      gut microbiota and can affect the efficacy of ICIs. Therefore, the present study 
      aimed to evaluate the influence of PPI on survival in patients with metastatic or 
      unresectable urothelial carcinoma receiving pembrolizumab. We conducted a 
      retrospective cohort study of patients with metastatic or unresectable urothelial 
      carcinoma receiving pembrolizumab. The use of PPI was defined as any 
      administration for >/=30 d within 60 d prior and/or 30 d after treatment 
      initiation. Overall survival (OS) and progression-free survival (PFS) were 
      estimated using the Kaplan-Meier method, and Cox proportional hazards regression 
      analysis was performed to investigate prognostic factors based on patient 
      characteristics. Seventy-nine patients were included in the analysis, and 34 
      patients (43.0%) received PPI. There were no significant differences in OS and 
      PFS between PPI users and nonusers (median OS: 8.2 months vs. 11.2 months, hazard 
      ratio (HR): 1.36, 95% confidence interval (CI): 0.75-2.42, p = 0.296; median PFS: 
      3.5 months vs. 5.1 months, HR: 1.63, 95% CI: 0.95-2.80, p = 0.069). In the 
      multivariable analysis, PPI use was not associated with OS (HR 0.80, 95% CI 
      0.40-1.56, p = 0.526) or PFS (HR 1.44, 95% CI 0.79-2.60, p = 0.233). In 
      conclusion, the estimated effect size of PPI use on survival in Japanese patients 
      with metastatic or unresectable urothelial carcinoma treated with pembrolizumab 
      was not reproducible.
FAU - Kunimitsu, Yoko
AU  - Kunimitsu Y
AD  - Department of Pharmacy, Kobe University Hospital.
FAU - Morio, Kayoko
AU  - Morio K
AD  - Department of Pharmacy, Kobe University Hospital.
FAU - Hirata, Sachi
AU  - Hirata S
AD  - Department of Pharmacy, Kobe University Hospital.
FAU - Yamamoto, Kazuhiro
AU  - Yamamoto K
AD  - Department of Pharmacy, Kobe University Hospital.
FAU - Omura, Tomohiro
AU  - Omura T
AD  - Department of Pharmacy, Kobe University Hospital.
FAU - Hara, Takuto
AU  - Hara T
AD  - Department of Urology, Kobe University Graduate School of Medicine.
FAU - Harada, Kenichi
AU  - Harada K
AD  - Department of Urology, Kobe University Graduate School of Medicine.
FAU - Fujisawa, Masato
AU  - Fujisawa M
AD  - Department of Urology, Kobe University Graduate School of Medicine.
FAU - Yano, Ikuko
AU  - Yano I
AD  - Department of Pharmacy, Kobe University Hospital.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Proton Pump Inhibitors)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - *Carcinoma, Transitional Cell/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Proton Pump Inhibitors
MH  - Retrospective Studies
MH  - *Urinary Bladder Neoplasms
OTO - NOTNLM
OT  - gut microbiome
OT  - pembrolizumab
OT  - proton pump inhibitor
OT  - survival
OT  - urothelial carcinoma
EDAT- 2022/05/02 06:00
MHDA- 2022/05/04 06:00
CRDT- 2022/05/01 21:54
PHST- 2022/05/01 21:54 [entrez]
PHST- 2022/05/02 06:00 [pubmed]
PHST- 2022/05/04 06:00 [medline]
AID - 10.1248/bpb.b21-00939 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2022;45(5):590-595. doi: 10.1248/bpb.b21-00939.